Based on linear regression of the allelic dose dependence for CD33 isoforms and AD risk, this 80 % reduction is calculated to reduce the AD odds ratio to 0.68, consistent with the possibility that this level of inhibition could be clinically meaningful. Here, CD33 is linked to Alzheimer disease.